Edgewise Therapeutics Inc. (EWTX)
$42.95
$1.00
(2.38%)
As on 04-Sep-2026 13:40EDT
Market cap
$4,644 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
10.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.9
-
Face value
--
-
Shares outstanding
108,604,129
5 Years Aggregate
CFO
$-201.90 Mln
EBITDA
$-203.92 Mln
Net Profit
$-184.24 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Edgewise Therapeutics (EWTX)
| 73.1 | 11.9 | 18.6 | 193.5 | 88.1 | 20.8 | -- |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Edgewise Therapeutics (EWTX)
| -7.1 | 142.3 | 22.4 | -41.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Edgewise Therapeutics (EWTX)
|
43.0 | 4,643.9 | 0.0 | -197.2 | -- | -40.7 | -- | 10.7 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 118.2 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Edgewise Therapeutics (EWTX)
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II... clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado. Read more
-
Co-Founder & Independent Chairman
Dr. Peter A. Thompson FACP, M.D.
-
Co-Founder & Independent Chairman
Dr. Peter A. Thompson FACP, M.D.
-
Headquarters
Boulder, CO
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Edgewise Therapeutics (EWTX)
What is the current share price of Edgewise Therapeutics Inc (EWTX) Today?
The share price of Edgewise Therapeutics Inc (EWTX) is $42.95 (NASDAQ) as of 04-Sep-2026 13:40 EDT. Edgewise Therapeutics Inc (EWTX) has given a return of 88.13% in the last 3 years.
What is the current PB & PE ratio of Edgewise Therapeutics Inc (EWTX)?
Since, TTM earnings of Edgewise Therapeutics Inc (EWTX) is negative, P/E ratio is not available.
The P/B ratio of Edgewise Therapeutics Inc (EWTX) is 10.71 times as on 28-Aug-2026, a 107 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-15.22 |
4.89 |
2024 |
-18.44 |
5.37 |
2023 |
-7.07 |
2.22 |
2022 |
-36.71 |
1.63 |
2021 |
-17.86 |
2.74 |
What is the 52 Week High and Low of Edgewise Therapeutics Inc (EWTX)?
The 52-week high and low of Edgewise Therapeutics Inc (EWTX) are Rs 48.40 and Rs 13.69 as of 05-Sep-2026.
What is the market cap of Edgewise Therapeutics Inc (EWTX)?
Edgewise Therapeutics Inc (EWTX) has a market capitalisation of $ 4,644 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Edgewise Therapeutics Inc (EWTX)?
Before investing in Edgewise Therapeutics Inc (EWTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.